rebamipide - 100 mg;
mannitol - 35.7 mg,
croscarmellose sodium - 14 mg,
pregelatinized starch - 80.7 mg,
sodium lauryl sulfate - 2 mg,
citric acid - 2.3 mg,
purified talcum powder - 3.1 mg,
magnesium stearate - 2.2 mg.
The composition of the film shell:
hypromellose - 2.77 mg,
purified talc - 0.57 mg,
titanium dioxide - 1.11 mg,
propylene glycol - 0.55 mg.
It has a cytoprotective effect against the gastric mucosa with the damaging effects of ethanol, acids and alkalis, acetylsalicylic acid.
It promotes the activation of enzymes that accelerate the biosynthesis of high molecular weight glycoproteins, and increases the content of mucus on the surface of the stomach wall.
It helps to improve the blood supply to the gastric mucosa, activates its barrier function, activates the alkaline secretion of the stomach, enhances the proliferation and metabolism of gastric epithelial cells, cleans the mucosa of hydroxyl radicals and suppresses superoxides produced by polymorphonuclear leukocytes and neutrophils in the presence of Helicobacter pylori, protects the mucosa from mucosa, protects the mucosa from mucosal infections has a gastroprotective effect when exposed to the mucosa of NSAIDs.
- stomach ulcer;
- chronic gastritis with increased acid-forming function of the stomach in the acute phase, erosive gastritis;
- prevention of damage to the mucous membrane while taking NSAIDs.
It can be used as part of combination therapy.
- individual intolerance to ribamipide or other components of the drug;
- lactation period;
- age to 18 years.
From the digestive system: constipation, flatulence, diarrhea, nausea, vomiting, pain in the abdomen, violation of taste sensations, heartburn.
From the liver: signs of liver dysfunction, increased serum ALT and ACT.
From the hemopoietic system: leukopenia, granulocytopenia.
Other: menstrual irregularities.
When using rebamipide as part of traditional treatment regimens for patients with Helicobacter pylori infection, the effectiveness of eradication therapy significantly increases.
Reactions with other drugs have not been studied.
How to take, course of administration and dosage
Inside, 1 tablet 3 times / day, washed down with a small amount of liquid. The course of treatment is 2-4 weeks, if necessary, can be extended up to 8 weeks.
The drug does not have action features at the first dose or when it is canceled.
If you skip taking one dose, you must take the next dose of the drug at the prescribed time, you should not take a double dose of the drug.
Symptoms of an overdose of rebamipide have not been described; to date, there have been no reports of deliberate overdose. Nausea, vomiting, abdominal pain, diarrhea or constipation, headache are possible.
Treatment: specific antidote unknown. In case of an overdose, the stomach should be washed and symptomatic therapy should be carried out.
Suction and distribution
After a dose of 100 mg, C max is reached after approximately 2 hours and is 340 ng / ml. Repeated doses of the drug do not lead to its cumulation in the body.
In vitro experiments have shown that from 98.4% to 98.6% of the drug binds to plasma proteins.
Metabolism and excretion
T 1/2 is approximately 1.0 hour. Approximately 10% of the drug is excreted by the kidneys, mainly unchanged. When taken in a dose of 600 mg, traces of a hydroxylated metabolite can be distinguished.
Impact on the ability to drive vehicles and mechanisms
The effect of the drug on the speed of psychomotor reactions and / or the ability to drive vehicles or mechanisms has not been studied. In the case of taking the drug, you should be careful about driving a car and other activities that require an increased concentration of attention.